Recent positive Phase 3 results from the INTerpath-001 trial have sharply shifted trader sentiment around potential FDA approval timelines for a personalized mRNA skin cancer vaccine. On August 19, 2026, Moderna and Merck announced that intismeran autogene (mRNA-4157/V940) combined with Keytruda met primary recurrence-free survival and key secondary distant metastasis-free survival endpoints in resected high-risk melanoma, marking the first such success for an individualized neoantigen mRNA therapy. The companies intend to present full data at an upcoming medical meeting such as ESMO 2026 and begin regulatory discussions for a filing. This development, building on durable five-year Phase 2b benefits, positions the combination for possible accelerated or priority review, though actual approval hinges on filing completeness, manufacturing scale-up for individualized production, and any additional data requirements. Other candidates, including IO Biotech's program, face steeper regulatory hurdles after recent FDA feedback.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedView resolved

Beware of external links.
Beware of external links.
Frequently Asked Questions